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Abstract
Purpose Longitudinal studies are needed to characterise the
burden of second primary malignancies among cancer survi-
vors. Therefore, we quantified the incidence rate and cumula-
tive incidence of second primary cancers (SPC) and
standardised incidence ratios (SIR) in a population-based co-
hort of subjects diagnosed with a first primary cancer (FPC).
Methods We evaluated a cohort of cancer patients from the
Portuguese North Region Cancer Registry (RORENO), with
the first diagnosis in 2000–2003 (n=39451), to estimate the
incidence rate and cumulative incidence of SPC and
standardised incidence ratios (SIR), for different periods of
follow-up, up to 5 years; SPC were defined according to the
International Association of Cancer Registries and the Inter-
national Agency for Research on Cancer guidelines.
Results The incidence rate of SPC was more than 5-fold
higher in the first 2 months of follow-up than in the period
between 2 months and 5 years (metachronous SPC), across
which the incidence rates were relatively stable. Cancer sur-
vivors had an overall higher incidence rate of cancer than the
general population (SIR=1.31 (95 % confidence interval (CI),
1.25–1.38)), although that difference faded when only
metachronous SPC were considered (SIR=1.02 (95 % CI,
0.96–1.08)). Cancer incidence rates were higher among fe-
male lung FPC survivors and lower in prostate FPC cancer
survivors than in the general population. The 5-year cumula-
tive risk of developing a metachronous SPC was 3.0 % and
reached nearly 5.0 % among patients with FPC associated
with lower risk of death.
Conclusions Cancer survivors had higher incident rates of
cancer that the general population, especially due to diagnoses
in the first months following the FPC. Nevertheless, after this
period SPC remain frequent events among cancer survivors.
Implications for cancer survivors SPC constitute an important
dimension of the burden of cancer survivorship, and this needs
to be taken into account when defining strategies for surveil-
lance, prevention and counselling.
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Introduction
The increasing number of incident cases of cancer [1] and the
improvements in survival [2] have been contributing to a
growing population of subjects with a previous diagnosis of
cancer. It was estimated that in 2012, there were more than 32
million cancer survivors worldwide [3]; these subjects have an
increased risk of several adverse health events and use of
health resources [4], including the recurrence of the first pri-
mary cancer (FPC), cardiovascular diseases or second primary
cancers (SPC) [5].
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The occurrence of SPC is mostly related to genetic
characteristics, persistence of deleterious environmental
exposures and late effects of FPC treatment [6].
Recognising frequent FPC-SPC pairs can also be a useful
starting point for investigating possible shared etiologies
and mechanisms of carcinogenesis. Quantifying and
characterising the risk of second malignancies can have
important implications for surveillance, prevention and
counselling.
SPC represented 16.0 % of all incident cancer cases in
USA (2003) [5], 6.3 % in Europe (1995–1999) [7] and
3.8 % in North Portugal (2000–2003) [8]. These differ-
ences in the frequency of SPC reflect the heterogeneous
distribution of cancer incidence and survival across set-
tings, as well as the distinct sensitivity of population-
based cancer registries with different operating times for
detecting SPC in cross-sectional analyses [7]. A longitu-
dinal assessment is expected to contribute to more accu-
rate estimates, and a better understanding of the burden of
SPC, by providing more clinically relevant measures of
incidence.
Therefore, we followed for 5 years in order a population-
based cohort of cancer survivors to estimate incidence rates of
SPC and corresponding standardised incidence ratios (SIR),
which reflect the dynamics of SPC diagnosis and their relation
with the expected cancer incidence in the general population.
Cumulative incidences of SPC were computed to quantify the
absolute risk of cancer survivors being diagnosed with another
primary cancer.
Methods
Study population and design
We conducted a cohort analysis based on the North Region
Cancer Registry (RORENO). This population-based cancer
registry (RORENO) was set up in 1988 and covers the whole
northern region of Portugal, corresponding to approximately
3.3 million inhabitants, which is nearly one third of the Por-
tuguese population.
All cases of cancer, other than skin non-melanoma, reg-
istered in the period 2000–2003, were followed for 5 years,
until the diagnosis of a new primary cancer or until death,
whichever occurred first; the vital status of the cancer pa-
tients was assessed through the National Health System
database.
Tumour topography and morphology were classified ac-
cording to the International Classification of Diseases for
Oncology, Third Edition (ICD-O-3) categories, and then
recoded to the International Statistical Classification of
Diseases and Related Health Problems 10th Revision
(ICD-10).
Definition of multiple primary cancers
To define multiple primary cancers (MPC), we followed
the guidelines proposed by the International Association
of Cancer Registries (IACR) and the International Agency
for Research on Cancer (IARC) [9]. Briefly, these criteria
consider primary cancers those that originally developed in
an organ or tissue, not being an extension, a recurrence or a
metastasis. Different morphologies (even with a same to-
pography) or dissimilar topographies should be regarded as
MPC, regardless of the time between the diagnoses, unless
they correspond to systemic cancers, which are considered
the same cancer.
Whenevermore than two primary cancers were observed in
the same patient, only the second primary cancer (SPC) was
considered; third and subsequent primary cancers were
disregarded for the present analysis.
We classified the SPC as synchronous when diagnosed
within 2 months of the corresponding FPC [10].
Statistical analysis
Person-years at risk (PYAR) among people diagnosed with a
FPC was calculated as the time from the diagnosis of the FPC
until 5 years of follow-up, date of death or date of diagnosis of
a SPC, whichever came first.
The incidence rate of SPC was computed for different
periods (B0 to <2 m^—from the diagnosis until less than
2 months of follow-up; B≥2 to <12 m^—from 2 months
unti l less than 12 months of follow-up; B≥12 to
≤60 m^—from 12 to 60 months of follow-up) since the
diagnosis of the FPC, by dividing the incident cases of
SPC by the PYAR within each time interval. Incidence
rates were estimated also for women and men and for the
most frequent types of FPC.
Standardised incidence ratios (SIRs) and corresponding
95% confidence intervals (95%CI), derived from the Poisson
distribution, were computed to evaluate age-adjusted ratios of
cancer incidence rates between cancer survivors and the gen-
eral population. The SIRs were calculated dividing the ob-
served number of SPC by the expected number of cancer
cases in the same period of time, if the cancer incidence rates
in the general population had been observed among cancer
survivors. The latter were estimated multiplying the PYAR
among cancer survivors by the sex- and age group-specific
cancer incidence rates observed in the general population of
North Portugal in 2006 [11].
We computed the cumulative incidence of metachronous
SPC and all-cause death for up to 5 years, stratified by sex and
the most frequent types of FPC. Cumulative incidence was
calculated by dividing the observed number of cases of SPC
or deaths until each period of analysis (2, 6, 12, 24, 36, 48 and
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60 months of follow-up) by the total number of survivors in
the beginning of the study.
All analyses were conducted using STATA®, version 9.2
(StataCorp LP, College Station, Texas, USA).
Results
Among the 39,451 patients with a FPC in 2000–2003, a
total of 1589 SPC were observed in the first 5 years after
the diagnosis of the FPC (120473 PYAR), from which 417
(26.2 %) were diagnosed within the first 2 months after the
FPC (synchronous tumours), 281 (17.7 %) between 2 or
more months and less than 1 year and 891 (56.1 %) be-
tween 1 and 5 years.
A total of 61.0 % of the SPC were observed among men
and 56.6 % in subjects aged 65 years or more. Regarding the
distribution according to the most common groups of SPC, in
relation with the observed for FPC diagnosed in 2000–2003,
during the 5-year follow-up, there was a lower proportion of
SPC of the female breast (6.8 vs. 12.4 %), prostate (8.1 vs.
11.9 %) and stomach (9.2 vs. 11.1 %) and a higher proportion
of cancer of the colon and rectum (13.3 vs. 10.0 % and 7.9 vs.
5.7 %, respectively), lung (10.7 vs. 7.9 %) and bladder (6.2 vs.
5.0 %) (Table 1).
Incidence rate of SPC and SIR
Overall, the incidence rate of SPC was more than 5-fold
higher in the first 2 months of follow-up than in the period
between 2 months and 5 years, across which the incidence
rates were relatively stable. However, the differences between
the 0- to <2-m and the ≥2- to ≤60-m periods were greater
among the individuals with stomach, colon, rectum and lung
FPC than among those with breast, prostate or bladder FPC
(Fig. 1).
The incidence rates observed among cancer survivors was
more than 30 % higher than the expected (SIR=1.31 (95 %
CI, 1.25–1.38)), especially among women (SIR women=1.73
(95 % CI, 1.60–1.88) vs. SIR men=1.13 (95 % CI, 1.06–
1.21)). This higher number of observed cases was mainly
identified during the first 2 months of follow-up (synchronous
SPC), and when this period was excluded from the analyses,
the SIR were much lower (SIR=1.02 (95 % CI, 0.96–1.08);
SIR women=1.28 (95 % CI, 1.17–1.41); SIR men=0.91
(95 % CI, 0.85–0.98)).
During the first 2 months of follow-up, the SIR were
higher, both among women (SIR=10.22 (95 % CI, 8.8–
11.8)) and men (SIR=4.86 (95 % CI, 4.3–5.5)); the results
were similar for the most frequent topographies of FPC
(Figs. 2 and 3).
Table 1 Characteristics of the
study cohort Total First primary cancer (FPC) Second primary cancer (SPC)
N % N %
Sex
Males 21,694 55.0 970 61.0
Females 17,757 45.0 619 39.0
Age at first diagnosis
0–14 307 0.8 4 0.3
15–49 years 7356 18.6 213 13.4
50–64 years 11,539 29.2 472 29.7
65 years and over 20,249 51.3 900 56.6
Follow-up interval
0 to <2 months n.a. 417 26.2
≥2 to <12 months n.a. 281 17.7
≥12 to <60 months n.a. 891 56.1
Topography
Stomach (C16) 4382 11.1 146 9.2
Colon (C18) 3955 10.0 211 13.3
Rectum (C19 and C20) 2240 5.7 125 7.9
Lung (C34) 3136 7.9 170 10.7
Bladder (C67) 1977 5.0 99 6.2
Female breast (C50) 4894 12.4 108 6.8
Prostate (C61) 4696 11.9 128 8.1
Other 14,171 35.9 602 37.9
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The incidence rate among female survivors was higher than
in the general population across the ≥2- to <12-m (SIR=1.37
(95 % CI, 1.13–1.67)) and the ≥12- to ≤60- (SIR=1.26 (95 %
CI, 1.13–1.40)) follow-up intervals (Fig. 2). For men, the in-
cidence rates were similar to those observed in the general
population in the same periods (≥2 to <12: SIR=0.91 (95 %
CI, 0.78–1.06); ≥12 to ≤60 m: SIR=0.91 (95 % CI, 0.84–
0.99)) (Fig. 3).
Among women, the SIR was lower in the ≥2- to <12-m
period for those with a breast FPC (SIR=0.36 (95 % CI,
0.17–0.76)). Those with a lung FPC were more likely to
develop a SPC during the ≥12- to ≤60-m period after the
diagnosis of the FPC (SIR=3.00 (95 % CI, 1.47–6.11)).
Among men, prostate cancer survivors showed a lower in-
cidence rate of cancer than the general population in the ≥2-
to <12-m (SIR=0.52 (95 % CI, 0.37–0.74)) and ≥12- to
≤60-m (SIR=0.67 (95 % CI, 0.58–0.78)) follow-up inter-
vals. After the first 2 months of follow-up, there were no
statistically significant differences in the cancer incidence
rates between the general population and the cancer survi-
vors with other FPC (Figs. 2 and 3).
Cumulative incidence of SPC and death
The 5-year cumulative incidence of SPC was 3.0 % (wom-
en, 2.5 %; men, 3.4 %) and the risk of death in the same
period was 46.1 % (women, 38.8 %; men, 52.1 %) (Fig. 4;
Appendix 1).
Womenwith FPC of the colon or bladder had the highest 5-
year risk of developing a SPC, 4.0 and 3.6 %, respectively,
along with a 5-year cumulative risk of death among the lowest
(colon, 46.2 %; bladder, 37.8 %). Those with lung and stom-
ach FPC had some of the lowest 5-year risk of developing a
SPC, 2.5 and 1.7 %, respectively, and the highest 5-year risk
of death (lung, 83.2 %; stomach, 62.0 %). Although the fe-
male breast cancer survivors had the lowest 5-year risk of
death (19.4 %), the 5-year risk of developing a SPC was also
among the lowest (2.2 %) (Fig. 5; Appendix 1).
Fig. 1 Trends in incidence rates of second primary cancers (SPC) since
the diagnosis of the corresponding first primary cancers (FPC). Incidence
rates were estimated and represented for the following intervals: B0 to
<2 months^; B≥2 to <6 months^; B≥6 to <12 months^; B≥12 to
<24 months^; B≥24 to <36 months^; B≥36 to <48 months^; B≥48 to
<60 months^
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Men with prostate and bladder FPC had the highest 5-year
cumulative incidence of SPC, 5.5 and 4.5 %, respectively, and
were among those with the lowest 5-year risk of death (pros-
tate, 25.0 %; bladder, 35.2 %). Subjects with a lung or a stom-
ach FPC had the lowest 5-year risk of a SPC, 1.2 and 2.7 %,
respectively, and were among those with highest 5-year risk of
death (lung, 87.8 %; stomach, 67.3 %) (Fig. 5).
Discussion
Cancer survivors had an overall higher incidence rate of can-
cer than the general population of North Portugal, although
that difference fades when only metachronous SPC are
considered. The 5-year cumulative risk of developing a SPC
was 3.0 % and reached nearly 5.0 % among patients with FPC
associated with lower risk of death.
The incidence rates of cancer were approximately 30 %
higher among cancer survivors, but similar to the observed
in the general population when only the metachronous SPC
were considered. The latter result is in agreement with a pre-
vious Finish study (SIR=0.99 (95 % CI, 0.95–1.03)) [12],
whereas higher incidence rates of metachronous SPC were
observed in Australia (SIR=1.27 (95 % CI, 1.25–1.29))
[13], France (SIR=1.36 (95 % CI, 1.35–1.38)) [14], Japan
(SIR=1.21 (95 % CI, 1.19–1.23)) [15] and the USA (SIR=
1.14 (95 % CI, 1.14–1.15)) [5], and lower rates were reported
in Danish (SIR=0.91 (95 % CI, 0.89–0.93)) [16], UK (SIR=
Fig. 2 Standardised incidence
ratios (SIR) and 95 % confidence
intervals (95 % CI) for the
diagnosis of a second primary
cancer, according to the first
primary cancer and follow-up
time since its diagnosis, among
women
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0.77 (95 % CI, 0.75–0.79)) [17] and Italian (SIR=0.93 (95 %
CI, 0.90–0.96)) [18] studies. The heterogeneity of these results
may reflect different patterns of cancer risk across populations
and periods analysed, as well as the use of distinct definitions
of SPC and synchronous tumours (intervals ranging from
2 months up to 1 year after the diagnosis of the FPC) and
differences in the length of follow-up.
Including synchronous SPC in the analyses allowed the
comparison of incidence rates since the diagnosis of the
FPC, which is seldom presented in other population-based
studies [18], and the assessment of the effect of diagnosis
anticipation in the incidence rates throughout follow-up.
In our study, more than one quarter of the SPC were synchro-
nous tumours, reflecting the strong influence of common di-
agnostic and staging procedures performed during the clinical
management of the FPC [19, 20]. This contributed to an in-
creased number of SPC diagnoses that otherwise would had
not been identified soon after the diagnosis of the FPC. Since
the FPC topographies with the highest incidence rates of SPC
in the first 2 months corresponded to the lowest incident rates
in the remaining 58 months of analysis, excluding the syn-
chronous SPC might have contributed to an underestimation
of the incidence rates after the first 2 months. Among our data,
we found that those FPC with more demanding staging
Fig. 3 Standardised incidence
ratios (SIR) and 95 % confidence
intervals (95 % CI) for the
diagnosis of a second primary
cancer, according to the first
primary cancer and follow-up
time since its diagnosis, among
men
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procedures at diagnosis (colon, rectum and lung tumours),
which usually include a CT scan and an endoscopic evalua-
tion, showed higher differences of incidence rate between the
0- to <2-m and the ≥2- to ≤60-m periods.
This tendency for anticipation of the diagnosis of a SPC
had already been recognised in previous studies, where 20–
30 % of all SPC diagnosed in the first 5 years were identified
within 2 months of the incidence date of the FPC [16, 18].
This phenomenon is analogous to the expected trend of the
incidence rate after a screening test, with a strong increase at
the beginning (synchronous FPC), when prevalent cases are
identified through anticipation of cancer diagnosis, followed
by a decrease due to the lack of diagnosis of cancers already
identified; afterwards, a smooth slope of further increase until
the usual incidence levels are reached again [21]. One exam-
ple that illustrates the impact of excluding a high number of
synchronous tumours in the quantification of metachronous
SIR, was observed in the UK study [17], which reported lower
SIR due to considering one of the largest synchronous periods
(12 months).
On other hand, several reports had documented that cancer
survivors with a more recent diagnosis had a higher SIR of
SPC than those diagnosed in earlier years [13, 15]. Although
the reasons for those differences are not yet completely under-
stood, cancer screening has been increasing during the past
decades [22] and is more frequent among cancer survivors
than in the general population [23], which may result in higher
SPC incidence rates in more recent years.
Beyond the strong influence of screening and surveillance
procedures in the increased incidence rates observed during
the first stages of survivorship, subtle genetic differences, FPC
treatment options and previous deleterious environmental ex-
posures should also be considered as potential determinants of
the observed SIRs. Future studies with Portuguese cancer
patients, using sizable samples analysing the potential role
of genetic polymorphisms, tobacco or ethanol consump-
tion and cancer treatment options (chemotherapy agents
or radiotherapy) as risk factors for the incidence of SPC
among survivors to different FPC, are awaited. The
change in behaviours after a cancer diagnosis should also
be considered an important determinant of SPC incidence
rates across different settings. A previous study from
North Portugal had shown similar patterns of lifestyle
exposures among cancer survivors and the general popu-
lation [24], although it was not clear if this was a conse-
quence of behavioural change or a survival bias, since the
study used a cross-sectional design.
Our results showed that prostate cancer survivors had low-
er incidence rate of cancer than the general population, when
analysing the entire follow-up period, in accordance to what
was observed in other settings [5, 13, 18]. A possible expla-
nation for those findings is the high proportion of prostate
cancers diagnosed by screening, which is more likely among
individuals with higher educational and socioeconomic status,
and consequently with a healthier profile than the general
population [25, 26].
Several studies have documented higher metachronous
cancer incidence rates among female breast cancer survivors
than in the general population [5, 13–15], essentially due to
tighter medical surveillance [20], a strong link between
hormonal-related cancers [27] and a genetic predisposition
(such as BRCA1 and BRCA2 syndromes) [28, 29]. However,
in our study, the rates in female breast cancer survivors were
similar to that observed in the general population. A plausible
explanation for this discrepancy is the high proportion (22 %)
of synchronous SPC that we observed in breast cancer survi-
vors, reflecting the anticipation of cancer diagnoses. When
considering both synchronous and metachronous SPC, the
Fig. 4 Cumulative risk of death and incidence of second primary cancers
(SPC), amongwomen andmen. Cumulative risks of death were estimated
and represented for the following intervals: B0 to <2 months^; B≥2 to
<6 months^; B≥6 to <12 months^; B≥12 to <24 months^; B≥24 to
<36 months^; B≥36 to <48 months^; B≥48 to <60 months^; cumulative
incidences of SPC were estimated and represented for the following
intervals: B≥2 to <6 months^; B≥6 to <12 months^; B≥12 to
<24 months^; B≥24 to <36 months^; B≥36 to <48 months^; B≥48 to
<60 months^
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Fig. 5 Cumulative risk of death
and incidence of second primary
cancers (SPC), for the most
frequent topographies of the first
primary cancers, among women
and men. Cumulative risks of
death were estimated and
represented for the following
intervals: B0 to <2 months^; B≥2
to <6 months^; B≥6 to
<12 months^; B≥12 to
<24 months^; B≥24 to
<36 months^; B≥36 to
<48 months^; B≥48 to
<60 months^; cumulative
incidences of SPC were estimated
and represented for the following
intervals: B≥2 to <6 months^; B≥6
to <12 months^; B≥12 to
<24 months^; B≥24 to
<36 months^; B≥36 to
<48 months^; B≥48 to
<60 months^
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observed SIR was 1.09 (95 % CI, 0.91–1.29), which is closer
to that observed in other studies [5]. Additionally, since a high
proportion of female breast cancers are diagnosed by screen-
ing and women adhering to screening tend to be more educat-
ed than the general population [30], wemay hypothesise that a
large proportion of these female cancer survivors had healthier
behaviour than the general population and, consequently, a
lower incidence rate of a SPC. The latter could have also
happened for colon and rectum FPCs, since the incidence rates
of these cancers is also likely to be influenced by screening
procedures.
Women with a lung FPC had a higher cancer incidence rate
than the general population, when considering the entire
follow-up period, although among men there were no signif-
icant differences. A lower competing risk of death among
women than in men with lung cancer [31] may contribute to
the differences observed. However, since in Portugal women
are at an earlier stage of the tobacco epidemic than men [32,
33], this may reflect mostly a more pronounced contrast be-
tween women with lung cancer and those from the general
population regarding the exposure to risk factors such as
smoking.
The FPCs with the highest survival rates had the highest 5-
year cumulative incidence of SPC. As observed in other set-
tings [5], these results are mostly likely explained by the com-
peting risk of death that contributes to a lower probability of
developing a SPC among the FPC topographies with worse
survival. We restricted our follow-up evaluation to 60 months,
because it was the longest time frame available with a com-
plete dataset regarding the studied variables. As this study
used data from a population-based cancer registry, this cohort
of patients diagnosed with a FPC within 2000–2003, will
continue to be followed up, allowing future evaluations with
longer time frames.
To our knowledge, this was the first study to estimate the 5-
year cumulative risk of developing a subsequent cancer
among cancer survivors in Portugal. The 5-year cumulative
incidence estimates were lower than those from the SEER,
which ranged between 2.8 and 8.9 %, respectively, for lung
and bladder FPC [5]. However, our results show that in North
Portugal, as in other settings, SPC should be regarded as a
problem commonly encountered in routine medical practice,
rather than a rare event. Moreover, data on the cumulative
incidence of SPC provides local clinicians with a benchmark
to estimate the probability of cancer survivors developing an-
other cancer within 5 years.
Despite the strengths of using data from a population-based
cancer registry, constituting an important piece of information
for understanding the burden of SPC in North Portugal, some
limitations need to be discussed.We only presented the overall
SIR of SPC across the most frequent FPC, due to the low
number of SPC in strata of less frequent FPC, precluding the
identification of frequent FPC-SPC pairs, which are a useful
starting point for investigating possible shared etiologies and
mechanisms of carcinogenesis. Survival is already high for
several cancers, and a longer follow-up is needed for a more
comprehensive understanding of the burden of SPC among
cancer survivors. The completeness of registration of SPC
may be higher than for FPC because cancer survivors have
contacted with the cancer registry sources when the FPC was
identified, which could contribute to an overestimation of
SIR; however, the completeness of the registry is high [34],
and this is not expected to have a major impact in the SIR
estimates. On the other hand, in patients already being follow-
ed, a new primary cancer may had been confused with recur-
rence, remaining unregistered; this is more likely to have oc-
curred, depending on the procedures implemented in each
source of data for the registry, contributing to an underestima-
tion of the number of SPC.
The population-based nature of the data used in our analy-
ses allows broad inference at a population level; however, the
interpretation of the results is limited by the absence of data on
the treatments to which each case was submitted, as well as
regarding their socioeconomic, behavioural or genetic charac-
teristics. Although high-penetrance mutations in cancer sus-
ceptibility genes, such in familial adenomatous polyposis
(FAP), hereditary nonpolyposis colorectal cancer (HNPCC),
BRCA1 and BRCA2 syndromes or Li-Fraumeni disease, are
estimated to make only a small contribution to the SPC bur-
den, owing to their low frequency [35], the prevailingmodel is
that genetic risk of both first and subsequent primary cancers
is defined by the cumulative effect of multiple low-penetrance
and intermediate-penetrance risk alleles for cancer, where
each individual genetic variant confers a modest increase in
risk, but which collectively increase risk substantially when
co-inherited in an individual [35]; the identification of cases
likely to be due to a high genetic susceptibility would allow a
better understanding of the determinants of the burden of SPC.
Finally, although we did not have data regarding the stage at
diagnosis of the FPC, precluding the assessment of its role
along the SPC incidence rates, we expect that those survivors
with lower stages at diagnosis will have higher incidence rates
of SPC, due to their expectedly higher survival.
In conclusion, cancer survivors had higher incident rates of
cancer than the general population, especially due to diagnoses
in the first months following the FPC. Nevertheless, after this
period SPC remain frequent events among cancer survivors
and constitute an important dimension of the burden of cancer
survivorship. This needs to be taken into account when defin-
ing strategies for surveillance, prevention and counselling.
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≥2 to <60 2.5 (2.2–2.7) 38.8 (37.9–39.7) 3.4 (3.2–3.7) 52.1 (51.1–53.1)
Stomach (C16) 0 to <12 0.5 (0.2–1.0) 40.3 (37.3–43.3) 0.7 (0.4–1.1) 43.9 (41.4–46.5)
≥2 to <36 1.3 (0.8–1.9) 57.6 (54.2–61.3) 1.9 (1.4–2.5) 61.7 (58.8–64.8)
≥2 to <60 1.7 (1.2–2.4) 62.0 (58.3–65.8) 2.7 (2.1–3.5) 67.3 (64.2–70.5)
Colon (C18) 0 to <12 0.7 (0.4–1.2) 20.5 (18.5–22.7) 0.7 (0.4–1.2) 20.6 (18.7–22.6)
≥2 to <36 2.6 (1.9–3.4) 39.0 (36.2–42.0) 2.5 (1.8–3.2) 38.3 (35.7–41.1)
≥2 to <60 4.0 (3.1–5.0) 46.2 (43.2–49.5) 3.8 (3.0–4.7) 47.4 (44.5–50.5)
Rectum (C19 and C20) 0 to <12 1.0 (0.5–1.8) 19.2 (16.5–22.2) 1.5 (0.9–2.3) 16.9 (14.7–19.3)
≥2 to <36 2.0 (1.2–3.1) 39.4 (35.5–43.6) 3.0 (2.1–4.1) 39.5 (36.2–43.1)
≥2 to <60 2.9 (1.9–4.2) 47.7 (43.5–52.4) 4.2 (3.1–5.4) 48.3 (44.7–52.3)
Lung (C34) 0 to <12 0.9 (0.3–2.1) 57.7 (51.6–64.3) 0.5 (0.3–0.9) 62.0 (59.0–65.1)
≥2 to <36 1.8 (0.9–3.3) 77.7 (70.5–85.3) 0.9 (0.6–1.4) 84.2 (80.7–87.8)
≥2 to <60 2.5 (1.4–4.2) 83.2 (75.8–91.1) 1.2 (0.8–1.7) 87.8 (84.3–91.5)
Bladder (C67) 0 to <12 1.1 (0.4–2.6) 18.5 (14.7–22.9) 1.5 (1.0–2.3) 14.5 (12.7–16.6)
≥2 to <36 2.7 (1.4–4.7) 31.3 (26.3–37.0) 3.8 (2.9–4.9) 28.6 (26.0–31.4)
≥2 to <60 3.6 (2.1–5.9) 37.8 (32.3–44.0) 5.5 (4.4–6.8) 35.2 (32.3–38.3)
Breast (C50) 0 to <12 0.2 (0.1–0.3) 3.7 (3.2–4.3)
≥2 to <36 1.2 (0.9–2.5) 12.9 (11.9–14.0)
≥2 to <60 2.2 (1.8–2.7) 19.4 (18.1–20.6)
Prostate (C61) 0 to <12 0.7 (0.5–1.0) 5.5 (4.8–6.2)
≥2 to <36 2.6 (2.2–3.1) 16.5 (15.3–17.7)
≥2 to <60 4.5 (3.9–5.1) 25.0 (23.5–26.4)
FPC first primary cancers, SPC second primary cancers, 95 % CI 95 % confidence interval
aMetachronous second primary cancers are those diagnosed in the period ≥2 to <12 months after the diagnosis of the first primary cancer
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